Aarti Pharmalabs Approves Unaudited Q1 FY27 Financial Results

Aarti Pharmalabs Ltd announced the approval of its unaudited financial results for the quarter ended June 30, 2026, both on a standalone and consolidated basis. The Board of Directors also approved a significant capacity addition for the development of an Intermediate Block with an estimated capital expenditure of Rs. 149 Crores. Additionally, key management changes were approved, including the appointment of Shri. Rashesh C. Gogri as Managing Director and Smt. Hetal Gogri Gala as Executive Director, both effective October 1, 2026, subject to shareholder approval. The company also announced the reconstitution of its Audit Committee, Corporate Social Responsibility Committee, and Stakeholders Relationship Committee.